These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 25400750)

  • 1. In vitro migratory aberrancies of mesenchymal stem cells derived from multiple myeloma patients only partially modulated by bortezomib.
    Xu X; Yang J; Tang Y; Li J; Zhu Y; Lu H; Fei X
    Int J Clin Exp Pathol; 2014; 7(10):6705-15. PubMed ID: 25400750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of proteasome inhibitor on migration ability and hepatocyte growth factor expression of bone marrow mesenchymal stem cells in multiple myeloma patients].
    Li JX; Fei XM; Lu H; Hu HJ; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1204-8. PubMed ID: 22040972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro anti-myeloma activity of TRAIL-expressing adipose-derived mesenchymal stem cells.
    Ciavarella S; Grisendi G; Dominici M; Tucci M; Brunetti O; Dammacco F; Silvestris F
    Br J Haematol; 2012 Jun; 157(5):586-98. PubMed ID: 22420897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib enhances the osteogenic differentiation capacity of human mesenchymal stromal cells derived from bone marrow and placental tissues.
    Sanvoranart T; Supokawej A; Kheolamai P; U-Pratya Y; Klincumhom N; Manochantr S; Wattanapanitch M; Issaragrisil S
    Biochem Biophys Res Commun; 2014 May; 447(4):580-5. PubMed ID: 24747566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling.
    Kaiser MF; Heider U; Mieth M; Zang C; von Metzler I; Sezer O
    Eur J Haematol; 2013 Apr; 90(4):263-72. PubMed ID: 23311753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of proteasome inhibitor PS-341 on the multiple cytokine expressions of mesenchymal stem cells from bone marrow in patients with multiple myeloma].
    Lin RF; Lu H; Liu P; Shen WY; Zhang JF; Wu YJ; Fei XM; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Feb; 14(1):61-4. PubMed ID: 16584593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow-derived mesenchymal stromal cells are attracted by multiple myeloma cell-produced chemokine CCL25 and favor myeloma cell growth in vitro and in vivo.
    Xu S; Menu E; De Becker A; Van Camp B; Vanderkerken K; Van Riet I
    Stem Cells; 2012 Feb; 30(2):266-79. PubMed ID: 22102554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib.
    Zhao Y; Zhang K; Li G; Zhang X; Shi D
    PLoS One; 2015; 10(5):e0127334. PubMed ID: 25973846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells.
    Kim J; Denu RA; Dollar BA; Escalante LE; Kuether JP; Callander NS; Asimakopoulos F; Hematti P
    Br J Haematol; 2012 Aug; 158(3):336-46. PubMed ID: 22583117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
    Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
    Kraus J; Kraus M; Liu N; Besse L; Bader J; Geurink PP; de Bruin G; Kisselev AF; Overkleeft H; Driessen C
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):383-96. PubMed ID: 26099967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microvesicles derived from normal and multiple myeloma bone marrow mesenchymal stem cells differentially modulate myeloma cells' phenotype and translation initiation.
    Dabbah M; Attar-Schneider O; Tartakover Matalon S; Shefler I; Jarchwsky Dolberg O; Lishner M; Drucker L
    Carcinogenesis; 2017 Jul; 38(7):708-716. PubMed ID: 28838065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib.
    Podar K; Shringarpure R; Tai YT; Simoncini M; Sattler M; Ishitsuka K; Richardson PG; Hideshima T; Chauhan D; Anderson KC
    Cancer Res; 2004 Oct; 64(20):7500-6. PubMed ID: 15492276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.
    Ma MH; Yang HH; Parker K; Manyak S; Friedman JM; Altamirano C; Wu ZQ; Borad MJ; Frantzen M; Roussos E; Neeser J; Mikail A; Adams J; Sjak-Shie N; Vescio RA; Berenson JR
    Clin Cancer Res; 2003 Mar; 9(3):1136-44. PubMed ID: 12631619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion.
    Neri P; Ren L; Azab AK; Brentnall M; Gratton K; Klimowicz AC; Lin C; Duggan P; Tassone P; Mansoor A; Stewart DA; Boise LH; Ghobrial IM; Bahlis NJ
    Blood; 2011 Jun; 117(23):6202-13. PubMed ID: 21474670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities.
    Ponte AL; Marais E; Gallay N; Langonné A; Delorme B; Hérault O; Charbord P; Domenech J
    Stem Cells; 2007 Jul; 25(7):1737-45. PubMed ID: 17395768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells.
    Markovina S; Callander NS; O'Connor SL; Kim J; Werndli JE; Raschko M; Leith CP; Kahl BS; Kim K; Miyamoto S
    Mol Cancer Res; 2008 Aug; 6(8):1356-64. PubMed ID: 18708367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
    Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
    Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple myeloma and bone marrow mesenchymal stem cells' crosstalk: Effect on translation initiation.
    Attar-Schneider O; Zismanov V; Dabbah M; Tartakover-Matalon S; Drucker L; Lishner M
    Mol Carcinog; 2016 Sep; 55(9):1343-54. PubMed ID: 26293751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib inhibits the angiogenesis mediated by mesenchymal stem cells.
    Wang X; Zhang Z; Yao C
    Cancer Invest; 2012 Nov; 30(9):657-62. PubMed ID: 23013101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.